Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zhaoke Ophthalmology Ltd. announced the approval of its Investigational New Drug application for Cyclosporine A Ophthalmic Gel by China’s NMPA, targeting treatment for dry eye disease, and also completed a pivotal Phase III trial for NVK002, aimed at controlling myopia in children. The company highlights the potential improvement in patient compliance and quality of life with its innovative treatments. With a burgeoning market for dry eye disease treatments in China and a focus on myopia prevention in the nation’s health plan, Zhaoke’s developments are positioned in a rapidly expanding healthcare segment.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.